DataString Consulting Company Logo
DataString Consulting Company Logo
Irbesartan Tablets Market
Home»Recent Reports»Irbesartan Tablets Market

Irbesartan Tablets Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802092, Published - March 2025

Segmented in Formulation Type (Immediate Release, Controlled Release), Dosage Strength (75mg, 150mg, 300mg), Usage Type, Patient Demographics, Prescription Type and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Irbesartan Tablets Market Outlook

The market, for Irbesartan tablets was estimated at $2.8 billion in 2024; and it is anticipated to increase to $3.7 billion by 2030 with projections indicating a growth to around $4.6 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 4.7% over the forecast period. The increasing importance of Irbesartan tablets in the sector is undeniable. The market has seen expansion owing to several reasons like the rising cases of hypertension and its affordability and easy accessibility. Its effectiveness in treating individuals with kidney issues linked to 2 diabetes has also made its mark. As a consequence the need for Irbesartan tablets is, on the rise enrichening its significance in today's landscape. The product has solidified its position, as a pharmaceutical ingredient that aligns with current healthcare standards and contemporary medicine techniques.


Irbesartan tablets, a key antihypertension drug in the pharmaceutical sphere, play a critical role in controlling high blood pressure, thereby reducing the risk of strokes and heart attacks. These tablets function by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently. Recently, there has been a shift towards personalized medication, resulting in an increased demand for Irbesartan tablets.


Market Size Forecast & Key Insights

2019
$2.8B2024
2029
$4.4B2034

Absolute Growth Opportunity = $1.6B

The Irbesartan Tablets market is projected to grow from $2.8 billion in 2024 to $4.4 billion in 2034. This represents a CAGR of 4.7%, reflecting rising demand across Hypertension Management, Diabetic Nephropathy Treatment and Heart Failure Therapy.

The Irbesartan Tablets market is set to add $1.6 billion between 2024 and 2034, with manufacturer targeting 150mg & 300mg Dosage Strength projected to gain a larger market share.

With Increased prevalence of hypertension, and Ageing global population, Irbesartan Tablets market to expand 58% between 2024 and 2034.

Opportunities in the Irbesartan Tablets Market

Strategic Collaborations to Accelerate Market Penetration

Consolidations of companies and collaborations, in the sector have a long history.

Tapping Into Unexplored Geographies and Technological Innovations Enhancing Availability

Currently in place are irbesartan tablets which are commonly prescribed for managing blood pressure and kidney issues linked to 2 diabetes. Primarily utilized in well developed regions with advanced healthcare facilities; nevertheless there exists a notable opportunity for producers to venture into emerging economies where awareness regarding chronic ailments is rising and healthcare spending is escalating steadily. Expanding into these markets holds the potential for significant growth, in the utilization of irbesartan tablets.

The rise of manufacturing technologies brings the potential to boost the output of irbesartan tablets significantly. By embracing these innovations and making investments in them manufacturers can expand their production capabilities to meet the increasing need for efficient solutions in managing blood pressure effectively. At the time the continuously changing landscape of online retail presents a direct avenue to connect with consumers directly overcoming distance barriers. When these factors come together it could lead to a rise, in the consumption of tablets.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

Across the globe in the Asia Pacific region irbesartan tablets are experiencing growth, fueled by a growing elderly population and the rising incidence of conditions like hypertension. Government efforts in health and improved affordability are key drivers of market expansion in this region. Yet significant competition from both local competitors poses a challenge, to capitalizing fully on the diverse market prospects available. This contest is actively promoting the creation of notch irbesartan tablets to improve patient results, in this region.

North America Outlook

In North America the rise in hypertension and heart related issues has led to the importance of irbesartan tablets in treatments becoming more pronounced. With developed healthcare systems and an increase in healthcare spending North America emerges as a promising market for irbesartan tablets. Its important to highlight that strict approval regulations and ongoing innovations in treatment methods reflect a competitive market. Market participants are actively creating product options to cater to the varying needs of individuals, with high blood pressure while expanding their market reach.

North America Outlook

In North America the rise in hypertension and heart related issues has led to the importance of irbesartan tablets in treatments becoming more pronounced. With developed healthcare systems and an increase in healthcare spending North America emerges as a promising market for irbesartan tablets. Its important to highlight that strict approval regulations and ongoing innovations in treatment methods reflect a competitive market. Market participants are actively creating product options to cater to the varying needs of individuals, with high blood pressure while expanding their market reach.

Asia-Pacific Outlook

Across the globe in the Asia Pacific region irbesartan tablets are experiencing growth, fueled by a growing elderly population and the rising incidence of conditions like hypertension. Government efforts in health and improved affordability are key drivers of market expansion in this region. Yet significant competition from both local competitors poses a challenge, to capitalizing fully on the diverse market prospects available. This contest is actively promoting the creation of notch irbesartan tablets to improve patient results, in this region.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, Japan, China are expected to grow at 3.3% to 4.3% CAGR

2

Emerging Markets : Brazil, Vietnam, South Africa are expected to grow at 5.2% to 6.6% CAGR

Market Analysis Chart

An in depth examination of the irbesartan tablets market dynamics shows that the irbesartan medication has factors driving its market expansion ahead. The main reason for the growth of the irbesartan tablets market comes from its effectiveness in managing hypertension. With hypertension cases rising at an alarming rate​ there is an increasing need for reliable treatment choices, like irbesartan tablets.

Recent Developments and Technological Advancement

December 2024

Sanofi revealed the initiation of a research initiative using AI technology to enhance the effectiveness of irbesartan tablets, for treating high blood pressure.

October 2024

A major advancement in the production technique by Pfizer Inc has resulted in a 25 % increase in the effectiveness of their irbesartan tablets, for better management of hypertension.

June 2024

GlaxoSmtihkline made a change to the irbesartan market by unveiling a new eco friendly packaging design for their irbesartan tablets that is more convenient, for patients.

The field of pharmaceuticals has shown advancements in how irbesartan tablets are made and distributed in recent times It appears that there has been a growing demand for this medication used to treat high blood pressure due to the rising number of hypertension cases worldwide One intriguing development in this sector is the increase in the production of generic irbesartan, as a more affordable option compared to branded tablets.

Impact of Industry Transitions on the Irbesartan Tablets Market

As a core segment of the Pharmaceutical industry, the Irbesartan Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Shift to Digital Pharmacy and Increased Focus on Generics have redefined priorities across the Pharmaceutical sector, influencing how the Irbesartan Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Shift to Digital Pharmacy:

The field of healthcare has experienced a transition to digital channels in recent years and this trend has also impacted the pharmaceutical sector greatly. In particular Irbesartan tablets are commonly recommended for managing conditions such as hypertension and kidney issues related to diabetes. This medication has now become readily available through online platforms where patients can conveniently order and receive their prescriptions at home reaping the advantages of online shopping, for medications. The availability of irbesartan tablets has been greatly enhanced through channels which is especially beneficial for individuals in remote areas or those facing challenges visiting a physical pharmacy store, in person. The online retail of irbesartan has experienced growth signifying the strong embrace of online pharmacies by consumers.

2

Increased Focus on Generics:

As the patents for branded medicines expire, generic versions of these drugs, which typically have the same active ingredients, flood the market. Irbesartan tablets, originally sold under the brand name Avapro, saw many generic versions enter the market post the expiration of its patent, causing a significant market shift.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Irbesartan Tablets market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Increased Prevalence of Hypertension

Irbesartan tablets are also primarily used to treat hypertension or high blood pressure—a condition on the rise due to factors like poor eating habits and lack of physical activity as well as genetic influences that call for better treatment options in response, to this growing health concern highlighted by the World Health Organizations data showing around 1.13 billion individuals globally dealing with hypertension with a significant portion residing in low to middle income nations. Irbesartan tablets are also expected to become more popular as a established medication, for treating high blood pressure because hypertension is also becoming more common.
The World Health Organization predicts that the% age of people aged 60 and above worldwide will also double to 22% by 2050 leading to a rise in hypertension and associated health issues. The risk of hypertension significantly increases with age highlighting the importance of treatments like irbesartan tablets in managing this condition. The increasing proportion of individuals is also anticipated to boost the demand for irbesartan tablets, in the market.

Restraint: Restrictive Regulatory Policies

Tougher rules in the sector are causing delays in approving irbesartan tablets and making them harder to get and expand in the market scene. Taking into account government guidelines like FDAs Good Manufacturing Practice rules and the European Unions Clinical Trials Directive forces pharmaceutical companies to invest more in research and development to meet these regulatory requirements. While this can lead to prices which may slow down the demand, in the market further.

Challenge: Public Perception and Misinformation

Although irbesartan tablets have proven effective in controlling blood pressure and kidney issues in individuals with diabetes. there is a lot of misinformation circulating about the possible side effects associated with them. The increased focus on health awareness has made people more wary of medications like irbesartan tablets. False information being shared on media platforms plays a role in tarnishing their reputation and eroding consumer trust. which can ultimately decrease their demand, in the market as a whole.

Supply Chain Landscape

API Production

Sanofi

Teva Pharmaceutical Industries

Formulation & Tablet Production

Aurobindo Pharma

Zydus Cadila

Distribution & Marketing
McKesson Corporation / Cardinal Health
Healthcare Providers
CVS Health / Walgreens Boots Alliance
API Production

Sanofi

Teva Pharmaceutical Industries

Formulation & Tablet Production

Aurobindo Pharma

Zydus Cadila

Distribution & Marketing

McKesson Corporation

Cardinal Health

Healthcare Providers

CVS Health

Walgreens Boots Alliance

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Hypertension Management
Pharmaceuticals
Sanofi
Sanofi emphasizes on extensive clinical trials ensuring long-lasting, safe and effective treatment.
Diabetic Nephropathy Prevention
Healthcare
Merck & Co.
Merck's strategic method involves a blend of patient advocacy outreach and comprehensive clinical research.
Heart Failure Treatment
Medical
GlaxoSmithKline Plc
GlaxoSmithKline's approach is to focus on unmet needs in cardiovascular conditions, including heart failure, by providing irbesartan tablets among their extensive medication regimen.
Reduction of Stroke Risks
Life Sciences
Pfizer Inc.
Pfizer's strategic stance revolves around proactive healthcare provisions; using irbesartan tablets to target high-risk individuals who might be susceptible to strokes.

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Irbesartan Tablets market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Irbesartan Tablets in Diabetic Nephropathy Treatment, Hypertension Management and Heart Failure Therapy

Diabetic Nephropathy Treatment

Irbesartan tablets are also used to treat nephropathy by administering 300mg tablets daily to patients, with kidney disease caused by diabetes. Pfizer and Aurobindi Pharma have excelled in this region by leveraging their distribution network and creative strategies to maximize the drugs effectiveness.

Hypertension Management

Irbesartan tablets are mainly prescribed for controlling blood pressure or hypertension by helping to relax and widen blood vessels for better blood flow and decreased pressure levels. Tor Pharma and Sanofi stand out as players in the pharmaceutical industry with their irbesartan tablet offerings for treating hypertension due to their focus on ongoing improvements, in processes and products.

Heart Failure Therapy

Irbesartan tablets can also be utilized as a treatment option for heart failure beyond their purpose based on certain research findings that indicate a potential reduction in stroke risk among heart failure patients by using this medication. As evidenced by the market presence demonstrated by companies like Merck and Novartis in this region due to their dedicated research and development initiatives Irbesartan tablets play a crucial role, in the management of heart related ailments.

Irbesartan Tablets vs. Substitutes:
Performance and Positioning Analysis

Irbesartan tablets, in comparison to alternatives such as Losartan and Valsartan, exhibit fewer side effects and improved efficacy, thus advancing their market positioning. This unique profile anticipates potential market growth

Irbesartan Tablets
    Effective in treating high blood pressure, positive impact on kidney health
    Possible side effects, risk of fetal toxicity
    Effective in controlling high blood pressure, fewer side effects
    Not all resistant to metabolic degradation, potential for drug-drug interactions

Irbesartan Tablets vs. Substitutes:
Performance and Positioning Analysis

Irbesartan Tablets

  • Effective in treating high blood pressure, positive impact on kidney health
  • Possible side effects, risk of fetal toxicity

Sparsentan Tablets / Valsartan Pills / Telmisartan Capsules

  • Effective in controlling high blood pressure, fewer side effects
  • Not all resistant to metabolic degradation, potential for drug-drug interactions

Irbesartan tablets, in comparison to alternatives such as Losartan and Valsartan, exhibit fewer side effects and improved efficacy, thus advancing their market positioning. This unique profile anticipates potential market growth

Loading...

Research Methodology

This market research methodology defines the Irbesartan Tablets market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Irbesartan Tablets across Immediate Release and Controlled Release Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Sanofi S.A., Mylan N.V., and Teva Pharmaceutical Industries Ltd. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including API Production, Formulation & Tablet Production, and Distribution & Marketing. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Irbesartan Tablets segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning API Production (Sanofi, Teva Pharmaceutical Industries), Formulation & Tablet Production (Aurobindo Pharma, Zydus Cadila), and Distribution & Marketing. Our parallel substitute analysis examines Sparsentan Tablets, Valsartan Pills, and Telmisartan Capsules, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Sanofi S.A., Mylan N.V., and Teva Pharmaceutical Industries Ltd., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Irbesartan Tablets market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Irbesartan Tablets Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 2.9 billion
Revenue Forecast in 2034USD 4.4 billion
Growth RateCAGR of 4.7% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 20242.8 billion
Growth OpportunityUSD 1.6 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 20242.8 billion USD
Market Size 20273.2 billion USD
Market Size 20293.5 billion USD
Market Size 20303.7 billion USD
Market Size 20344.4 billion USD
Market Size 20354.6 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredFormulation Type, Dosage Strength, Usage Type, Patient Demographics, Prescription Type
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledSanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Lupin Limited, Aurobindo Pharma, Dr. Reddy's Laboratories, Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Novartis International AG and Accord Healthcare.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Irbesartan Tablets Market Size, Opportunities & Strategic Insights, by Formulation Type

4.1Immediate Release
4.2Controlled Release
Chapter 5

Irbesartan Tablets Market Size, Opportunities & Strategic Insights, by Dosage Strength

5.175mg
5.2150mg
5.3300mg
Chapter 6

Irbesartan Tablets Market Size, Opportunities & Strategic Insights, by Usage Type

6.1Hospital Pharmacies
6.2Retail Pharmacies
6.3E-Commerce
Chapter 7

Irbesartan Tablets Market Size, Opportunities & Strategic Insights, by Patient Demographics

7.1Adults
7.2Geriatrics
7.3Pediatrics
Chapter 8

Irbesartan Tablets Market Size, Opportunities & Strategic Insights, by Prescription Type

8.1Rx
8.2OTC
Chapter 9

Irbesartan Tablets Market, by Region

9.1North America Irbesartan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Irbesartan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Irbesartan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Irbesartan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Irbesartan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Irbesartan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Sanofi S.A.
10.2.2Mylan N.V.
10.2.3Teva Pharmaceutical Industries Ltd.
10.2.4Zydus Cadila
10.2.5Lupin Limited
10.2.6Aurobindo Pharma
10.2.7Dr. Reddy's Laboratories
10.2.8Alembic Pharmaceuticals Ltd.
10.2.9Torrent Pharmaceuticals Ltd.
10.2.10Sun Pharmaceutical Industries Ltd.
10.2.11Novartis International AG
10.2.12Accord Healthcare.